ArticleBiomedicines2022

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC).

Joanna Bialek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.